Telix Strengthens Radiopharmaceutical Pipeline with Multiple Late-Stage Clinical Milestones

Melbourne, Australia and Indianapolis, Indiana, U.S. | August 20, 2026

Radiopharmaceutical Pipeline Advances Across Oncology Programs

Telix’s therapeutic pipeline delivered several important clinical development milestones during H1 2026. The company’s lead prostate cancer radiopharmaceutical candidate TLX591-Tx advanced through the ProstACT Global program, with the Part 1 lead-in meeting its safety and dosimetry objectives and enabling progression of Part 2 in the United States. Recruitment is continuing across multiple international markets. Meanwhile, the TLX597-Tx program reached a major enrollment milestone after the OPTIMAL-PSMA Phase 2 investigator-initiated study completed enrollment of 120 patients in metastatic castration-resistant prostate cancer, while the OPTIMAL-e study in metastatic hormone-sensitive prostate cancer dosed its first patients. These developments reinforce Telix’s focus on expanding targeted radionuclide therapy across different stages of prostate cancer.

Multiple Late-Stage Programs Move Forward

Beyond prostate cancer, Telix advanced radiopharmaceutical candidates targeting kidney cancer and glioblastoma, broadening its oncology development portfolio. The company dosed the first patient in LUTEON, a pivotal study evaluating TLX250-Tx as monotherapy in advanced clear cell renal cell carcinoma. In glioblastoma, TLX101-Tx entered the next stage of development through the IPAX BrIGHT pivotal program, while enrollment was completed in the IPAX-2 Phase 1 study for newly diagnosed disease. Telix also reported regulatory progress for its precision imaging portfolio, including an FDA PDUFA goal date of September 11, 2026, for Pixclara, alongside European review activity for Pixlumi. These regulatory and clinical milestones create multiple potential catalysts across Telix’s diagnostic and therapeutic radiopharmaceutical portfolio.

Manufacturing Infrastructure Supports Pipeline Expansion

Manufacturing and supply-chain capabilities remain a central component of Telix’s strategy, particularly as the company moves several radiopharmaceutical candidates toward later-stage development and potential commercialization. Telix Manufacturing Solutions reported US$146 million in segment revenue, including US$89 million from third-party product sales and service fees. The company continued expanding its global manufacturing footprint through facilities and operations spanning the United States, Belgium, Australia and Japan. During H1, the Seneffe facility in Belgium completed its first GMP production run of a lutetium-based therapeutic candidate, an important manufacturing milestone for future radiopharmaceutical production. Telix also opened its North Melbourne operation in partnership with the Melbourne Theranostic Innovation Centre to support development of targeted radiopharmaceuticals. The company invested US$124 million in R&D, with US$68 million directed toward its therapeutics pipeline, demonstrating the scale of investment behind its late-stage programs. Telix also entered a strategic collaboration with Regeneron for next-generation radiopharmaceutical therapies and received a US$40 million non-refundable payment under the collaboration. The company ended June with US$252 million in cash and reaffirmed FY2026 revenue guidance of US$950 million to US$970 million, while expecting revenue and other income to exceed US$1 billion. Overall, Telix’s H1 update highlights a combination of commercial execution, clinical-stage radiopharmaceutical advancement, regulatory progress and manufacturing expansion, with multiple oncology programs approaching important development milestones.

Source:Telix Pharmaceuticals press relese